On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00. Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment. buying long term calls could be a strategy for this one. volatility is...
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support. The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data...
Took the chart all the way back out to 2015 to find some relevant levels and did a quick fib retracement. Aside from the 236 level being a key point of resistance, in 2015, the area around $5.20 presented an interesting area of high traffic. SESN managed to break through this briefly but as you'll see, it was fleeting after putting in the top that I used as the...
the chart and the board always are talking us for bright future
as i told you ..the gap should filled before fda approval for the new era and many ATH pt is $12 short term and long term $20 the 2 gaps are the red rectangles . V shape at our chart ONLY LONG
above 10,21,50 MA and out of downtrend line before approval $12 is coming veery soon
100% sure the approval and there we 28% short covering and the new era will start my pt is 10-12 $$ short term
strong long close to approval and take of!!
we broke out 21MA today !!! fda approval soon
first pt is $7,5 we are waiting fda approval
I'll just say that there are a lot of stocks and cryptos reaching breaking points, and they will most likely all do the same thing. I'm seeing plenty of potential for most everything to break to the downside but the bullish charts look strong so that's what I'm going with. This SESN chart looks really good, but it's at the tipping point as we speak.
On the verge of FDA approval for a new product, multiple analysts recently adjusting price targets to $6 plus. In a market full of mania, a stock with good fundamentals may get overhyped especially about something as legitimate as FDA approval. Who's not talking about SESN and ENZC right now??? If FDA approval falls through both stocks will suffer a lot, so be...
While it is historically (and notoriously if you're any kind of long in it already) a slow-moving biotech stock, when these sudden capitulation dips occur is when smart setups present themselves and the stock runs past previous support/resistance levels off pure momentum rallies from the lows in the large symmetrical triangle pattern. A potential run such as this...
Long over 2.00. showing strength in a down market day. $SESN $XBI